Plus Therapeutics, Inc.(PSTV)Earnings, Financials & Key Ratios
PSTV•NASDAQ
$6.00
$15M mkt cap·Price updated May 6, 2026
AboutPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Show more
- Revenue$5M-10.5%
- EBITDA-$15M-7.3%
- Net Income-$22M-72.5%
- EPS (Diluted)-7.19+100.0%
- Gross Margin91.46%+7.1%
- EBITDA Margin-284.92%-19.9%
- Operating Margin-293.46%-16.3%
- Net Margin-429.43%-92.7%
- ROE-560.21%
- Debt/Equity0.21
- Interest Coverage-4.24-70.6%
PSTV Key Insights
Plus Therapeutics, Inc. (PSTV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 76.7%
✗Weaknesses
- ✗Profits declining 22.1% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PSTV Price & Volume
Plus Therapeutics, Inc. (PSTV) stock price & volume — 10-year historical chart
Loading chart...
PSTV Growth Metrics
Plus Therapeutics, Inc. (PSTV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.73%
5 Years76.66%
3 Years185.5%
TTM-10.49%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-72.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.68%
Return on Capital
10 Years-149.53%
5 Years-214.68%
3 Years-295.79%
Last Year-381.4%
PSTV Peer Comparison
Plus Therapeutics, Inc. (PSTV) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 CLDX | 2.29B | 34.39 | -8.82 | -78.63% | -172.53% | -49.09% | 0.00 | |
 IART | 1.09B | 14.00 | -2.08 | 1.53% | -30.15% | -47.65% | 1.95 | |
 ACTG | 489.13M | 5.07 | 23.05 | 133.2% | 7.6% | 3.75% | 0.17 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ARAY | 58.45M | 0.49 | -31.75 | 2.68% | -10.76% | -77.48% | 2.17 | |
 BNGO | 13.64M | 1.27 | -0.26 | -7.37% | -92.59% | -56.22% | 0.16 |
Compare PSTV vs Peers
Plus Therapeutics, Inc. (PSTV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PSTV Income Statement
Plus Therapeutics, Inc. (PSTV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.41M | 2.98M | 7M | 303K | 0 | 224K | 4.91M | 5.82M | 5.21M |
| Revenue Growth % | -43.66% | -53.47% | 134.6% | -95.67% | -100% | - | 2093.3% | 18.54% | -10.49% |
| Cost of Goods Sold | 1.32M | 1.15M | 0 | 2.7M | 66K | 712K | 9.69M | 852K | 445K |
| COGS % of Revenue | 20.56% | 38.48% | - | 891.09% | - | 317.86% | 197.23% | 14.63% | 8.54% |
| Gross Profit | 5.09M▲ 0% | 1.83M▼ 64.0% | 7M▲ 281.4% | -2.4M▼ 134.3% | -66K▲ 97.2% | -488K▼ 639.4% | -4.78M▼ 878.9% | 4.97M▲ 204.1% | 4.77M▼ 4.1% |
| Gross Margin % | 79.44% | 61.52% | 100% | -791.09% | - | -217.86% | -97.23% | 85.37% | 91.46% |
| Gross Profit Growth % | -41.22% | -63.97% | 281.36% | -134.25% | 97.25% | -639.39% | -878.89% | 204.08% | -4.1% |
| Operating Expenses | 25.78M | 10.77M | 10.65M | 7.19M | 12.43M | 19.22M | 8.54M | 19.67M | 20.07M |
| OpEx % of Revenue | 402.06% | 360.91% | 152.26% | 2371.95% | - | 8582.14% | 173.91% | 337.69% | 384.92% |
| Selling, General & Admin | 11.19M | 6.22M | 5.29M | 6.41M | 6.85M | 9.53M | 8.54M | 9.94M | 12.13M |
| SG&A % of Revenue | 174.5% | 208.58% | 75.59% | 2114.19% | - | 4252.68% | 173.91% | 170.66% | 232.73% |
| Research & Development | 13.36M | 5.52M | 5.37M | 3.48M | 5.32M | 9.7M | 9.69M | 10.58M | 8.38M |
| R&D % of Revenue | 208.45% | 185.15% | 76.66% | 1148.84% | - | 4329.46% | 197.23% | 181.66% | 160.73% |
| Other Operating Expenses | 1.23M | -1.15M | 0 | -2.7M | 250K | 0 | -9.69M | -852K | -445K |
| Operating Income | -20.68M▲ 0% | -8.76M▲ 57.6% | -3.66M▲ 58.3% | -9.58M▼ 162.1% | -12.49M▼ 30.3% | -19.71M▼ 57.8% | -13.32M▲ 32.4% | -14.7M▼ 10.3% | -15.3M▼ 4.1% |
| Operating Margin % | -322.62% | -293.73% | -52.26% | -3163.04% | - | -8800% | -271.14% | -252.32% | -293.46% |
| Operating Income Growth % | -4.96% | 57.64% | 58.26% | -162.07% | -30.34% | -57.8% | 32.42% | -10.31% | -4.1% |
| EBITDA | -18.53M | -6.76M | -2.76M | -9.22M | -12.07M | -19M | -12.69M | -13.84M | -14.85M |
| EBITDA Margin % | -289.07% | -226.55% | -39.45% | -3042.24% | - | -8482.14% | -258.36% | -237.69% | -284.92% |
| EBITDA Growth % | -0.04% | 63.53% | 59.14% | -233.86% | -30.97% | -57.38% | 33.19% | -9.06% | -7.3% |
| D&A (Non-Cash Add-back) | 2.15M | 2M | 896K | 366K | 419K | 712K | 628K | 852K | 445K |
| EBIT | -20.64M | -6.96M | -1.43M | -8.8M | -12.47M | -19.56M | -13.32M | -9.25M | -15.3M |
| Net Interest Income | -2.02M | -1.88M | -1.8M | -1.06M | -913K | -564K | 5K | -3.45M | -3.49M |
| Interest Income | 33K | 43K | 55K | 50K | 19K | 147K | 400K | 273K | 116K |
| Interest Expense | 2.05M | 1.92M | 1.85M | 1.11M | 932K | 711K | 395K | 3.72M | 3.61M |
| Other Income/Expense | -2M | -116K | 374K | 1.34M | -907K | -563K | 5K | 1.72M | -7.09M |
| Pretax Income | -22.69M▲ 0% | -8.88M▲ 60.9% | -3.28M▲ 63.0% | -8.24M▼ 151.0% | -13.4M▼ 62.6% | -20.27M▼ 51.3% | -13.32M▲ 34.3% | -12.98M▲ 2.5% | -22.39M▼ 72.5% |
| Pretax Margin % | -353.86% | -297.62% | -46.91% | -2719.8% | - | -9051.34% | -271.04% | -222.84% | -429.43% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -22.69M▲ 0% | -12.63M▲ 44.3% | -10.89M▲ 13.8% | -8.24M▲ 24.3% | -13.4M▼ 62.6% | -20.27M▼ 51.3% | -13.32M▲ 34.3% | -12.98M▲ 2.5% | -22.39M▼ 72.5% |
| Net Margin % | -353.86% | -423.53% | -155.57% | -2719.8% | - | -9051.34% | -271.04% | -222.84% | -429.43% |
| Net Income Growth % | -2.9% | 44.31% | 13.83% | 24.3% | -62.59% | -51.32% | 34.32% | 2.54% | -72.49% |
| Net Income (Continuing) | -22.69M | -8.88M | -3.28M | -8.24M | -13.4M | -20.27M | -13.32M | -12.98M | -22.39M |
| Discontinued Operations | 0 | -3.76M | -7.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -999999.00▲ 0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -697500.00▲ 30.2% | -444500.00▲ 36.3% | -288750.00▲ 35.0% | -106000.00▲ 63.3% | -58500.00▲ 44.8% | -7.19▲ 100.0% |
| EPS Growth % | 45.27% | 75.17% | 89.42% | 79.8% | 36.27% | 35.04% | 63.29% | 44.81% | 99.99% |
| EPS (Basic) | -999999.00 | -999999.00 | -999999.00 | -697500.00 | -444500.00 | -288750.00 | -106000.00 | -48750.00 | -7.19 |
| Diluted Shares Outstanding | 17 | 0 | 4 | 12 | 32 | 70 | 126 | 308 | 3.11M |
| Basic Shares Outstanding | 17 | 0 | 4 | 12 | 32 | 70 | 126 | 266 | 3.11M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PSTV Balance Sheet
Plus Therapeutics, Inc. (PSTV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.86M | 9.65M | 19.82M | 9.18M | 19.72M | 21.82M | 9.83M | 5.26M | 15.17M |
| Cash & Short-Term Investments | 9.55M | 5.26M | 17.55M | 8.35M | 18.4M | 18.12M | 8.55M | 3.61M | 8.76M |
| Cash Only | 9.55M | 5.26M | 17.55M | 8.35M | 18.4M | 18.12M | 8.55M | 76K | 8.76M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.53M | 0 |
| Accounts Receivable | 257K | 233K | 1.31M | 59K | 7K | 0 | 0 | 571K | 0 |
| Days Sales Outstanding | 14.63 | 28.51 | 68.48 | 71.07 | - | - | - | 35.79 | - |
| Inventory | 3.18M | 107K | 107K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 881.48 | 34.02 | - | - | - | - | - | - | - |
| Other Current Assets | 675K | 3.32M | 40K | 0 | 0 | 0 | 0 | 1.08M | 6.41M |
| Total Non-Current Assets | 16.75M | 14.34M | 3.4M | 2.93M | 2.26M | 2.05M | 1.55M | 1.37M | 1.16M |
| Property, Plant & Equipment | 3.05M | 2.3M | 2.96M | 2.46M | 1.82M | 1.57M | 1.11M | 521K | 327K |
| Fixed Asset Turnover | 2.10x | 1.30x | 2.36x | 0.12x | - | 0.14x | 4.43x | 11.18x | 15.94x |
| Goodwill | 3.92M | 372K | 372K | 372K | 372K | 372K | 372K | 372K | 372K |
| Intangible Assets | 7.21M | 0 | 0 | 86K | 51K | 94K | 42K | 469K | 333K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.57M | 11.67M | 72K | 16K | 16K | 12K | 32K | 12K | 123K |
| Total Assets | 31.61M▲ 0% | 23.99M▼ 24.1% | 23.23M▼ 3.2% | 12.11M▼ 47.9% | 21.98M▲ 81.6% | 23.87M▲ 8.6% | 11.39M▼ 52.3% | 6.63M▼ 41.8% | 16.32M▲ 146.1% |
| Asset Turnover | 0.20x | 0.12x | 0.30x | 0.03x | - | 0.01x | 0.43x | 0.88x | 0.32x |
| Asset Growth % | -8.65% | -24.12% | -3.18% | -47.89% | 81.59% | 8.58% | -52.29% | -41.75% | 146.12% |
| Total Current Liabilities | 18.41M | 17.56M | 14.49M | 8.54M | 5.87M | 11.85M | 10.73M | 15.55M | 12.31M |
| Accounts Payable | 1.3M | 721K | 327K | 789K | 2.61M | 8.36M | 4.76M | 9.47M | 0 |
| Days Payables Outstanding | 359.18 | 229.24 | - | 106.66 | 14.44K | 4.29K | 179.22 | 4.06K | - |
| Short-Term Debt | 13.62M | 14.2M | 11.06M | 6.33M | 1.61M | 1.72M | 3.98M | 3.29M | 806K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 225K | 973K | 1.99M | 299K | 374K | 346K | 370K | 2.74M | 11.51M |
| Current Ratio | 0.81x | 0.55x | 1.37x | 1.07x | 3.36x | 1.84x | 0.92x | 0.34x | 1.23x |
| Quick Ratio | 0.63x | 0.54x | 1.36x | 1.07x | 3.36x | 1.84x | 0.92x | 0.34x | 1.23x |
| Cash Conversion Cycle | 536.93 | -166.71 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 201K | 1.21M | 7.58M | 535K | 5.28M | 5.57M | 2.01M | 31K | 15K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 5M | 3.79M | 0 | 0 | 15K |
| Capital Lease Obligations | 0 | 0 | 646K | 528K | 269K | 141K | 85K | 31K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 107K | 1.04M | 6.94M | 7K | 1K | 1.64M | 1.92M | 0 | 0 |
| Total Liabilities | 18.61M | 18.77M | 22.07M | 9.07M | 11.14M | 17.42M | 12.74M | 15.58M | 12.33M |
| Total Debt | 13.62M | 14.2M | 11.97M | 7M | 6.99M | 5.75M | 4.18M | 3.37M | 821K |
| Net Debt | 4.07M | 8.94M | -5.58M | -1.35M | -11.41M | -12.37M | -4.37M | 3.29M | -7.94M |
| Debt / Equity | 1.05x | 2.72x | 10.32x | 2.31x | 0.65x | 0.89x | - | - | 0.21x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -10.07x | -3.62x | -0.77x | -7.95x | -13.38x | -27.52x | -33.72x | -2.48x | -4.24x |
| Total Equity | 13M▲ 0% | 5.22M▼ 59.8% | 1.16M▼ 77.8% | 3.03M▲ 161.3% | 10.84M▲ 257.5% | 6.45M▼ 40.5% | -1.35M▼ 120.9% | -8.95M▼ 563.9% | 4M▲ 144.7% |
| Equity Growth % | 18.33% | -59.81% | -77.8% | 161.29% | 257.51% | -40.52% | -120.92% | -563.87% | 144.65% |
| Book Value per Share | 752551.00 | 999999.00 | 314305.22 | 256699.94 | 336127.16 | 92053.02 | -10729.32 | -29051.42 | 1.28 |
| Total Shareholders' Equity | 13M | 5.22M | 1.16M | 3.03M | 10.84M | 6.45M | -1.35M | -8.95M | 4M |
| Common Stock | 6K | 0 | 4K | 7K | 16K | 34K | 5K | 6K | 139K |
| Retained Earnings | -401.75M | -414.38M | -425.27M | -433.51M | -446.91M | -467.19M | -480.5M | -493.48M | -515.87M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -126K | -500K | 0 |
| Accumulated OCI | 1.39M | 1.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PSTV Cash Flow Statement
Plus Therapeutics, Inc. (PSTV) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.13M | -11.97M | -5.91M | -8.43M | -10.28M | -12.97M | -12.85M | -10.55M | -20.77M |
| Operating CF Margin % | -282.76% | -401.44% | -84.4% | -2783.5% | - | -5791.07% | -261.57% | -181.22% | -398.52% |
| Operating CF Growth % | 7.19% | 33.94% | 50.68% | -42.8% | -21.89% | -26.19% | 0.93% | 17.87% | -96.84% |
| Net Income | -22.69M | -12.63M | -10.89M | -8.24M | -13.4M | -20.27M | -13.32M | -12.98M | -22.39M |
| Depreciation & Amortization | 2.15M | 2M | 896K | 366K | 395K | 619K | 628K | 723K | 445K |
| Stock-Based Compensation | 753K | 355K | 127K | 247K | 606K | 606K | 569K | 550K | 1.54M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.69M | -668K | 4.9M | -925K | 880K | 481K | 384K | -2.07M | 5.67M |
| Working Capital Changes | -1.04M | -1.03M | -938K | 119K | 1.24M | 5.6M | -1.12M | 3.22M | -6.04M |
| Change in Receivables | 1.13M | -173K | -1.2M | 1.17M | 0 | 0 | 0 | -571K | 249K |
| Change in Inventory | 251K | 475K | 259K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.82M | -1.42M | -23K | -1.23M | 1.73M | 0 | -3.68M | 4.7M | -5.62M |
| Cash from Investing | -1.38M | -133K | 5.57M | -493K | -82K | -759K | -160K | -4.11M | -854K |
| Capital Expenditures | -1.5M | -133K | -67K | -93K | -144K | -509K | -160K | -146K | -67K |
| CapEx % of Revenue | 23.33% | 4.46% | 0.96% | 30.69% | - | 227.23% | 3.26% | 2.51% | 1.29% |
| Acquisitions | 0 | 0 | 5.64M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 113K | 0 | 0 | -400K | 62K | -250K | 0 | -545K | 30K |
| Cash from Financing | 16.82M | 7.17M | 12.63M | -319K | 20.42M | 13.45M | 3.44M | 6.19M | 30.31M |
| Debt Issued (Net) | -4.72M | 0 | -3.82M | -5.42M | -276K | -1.61M | -1.61M | -704K | -4.76M |
| Equity Issued (Net) | 21.54M | 7.23M | 15.96M | 4.01M | 18.68M | 15.83M | 5.4M | 6.89M | 15.7M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -2.08M | 0 | 0 | 0 | 0 | 0 | -126K | -374K | 0 |
| Other Financing | 0 | -66K | 490K | 1.1M | 2.02M | -773K | -348K | 0 | 19.37M |
| Net Change in Cash | -2.33M▲ 0% | -4.92M▼ 110.9% | 12.29M▲ 349.6% | -9.25M▼ 175.2% | 10.05M▲ 208.7% | -280K▼ 102.8% | -9.57M▼ 3316.4% | -8.48M▲ 11.4% | 8.68M▲ 202.4% |
| Free Cash Flow | -19.62M▲ 0% | -12.11M▲ 38.3% | -5.97M▲ 50.7% | -8.93M▼ 49.5% | -10.42M▼ 16.8% | -13.73M▼ 31.7% | -13.01M▲ 5.2% | -10.7M▲ 17.8% | -20.84M▼ 94.8% |
| FCF Margin % | -306.1% | -405.9% | -85.35% | -2946.2% | - | -6129.91% | -264.83% | -183.72% | -399.81% |
| FCF Growth % | -0.12% | 38.3% | 50.67% | -49.46% | -16.77% | -31.72% | 5.24% | 17.76% | -94.78% |
| FCF per Share | -999999.00 | -999999.00 | -999999.00 | -756041.04 | -323347.13 | -196117.92 | -103560.26 | -34735.75 | -6.70 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.95x | 0.54x | 1.02x | 0.77x | 0.64x | 0.97x | 0.81x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 327K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PSTV Key Ratios
Plus Therapeutics, Inc. (PSTV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -190.12% | -189.16% | -138.64% | -341.02% | -393.27% | -193.25% | -234.65% | -522.5% | - | -560.21% |
| Return on Invested Capital (ROIC) | -96.56% | -93.63% | -42.07% | -56.28% | - | -1688.11% | - | - | - | - |
| Gross Margin | 76.14% | 79.44% | 61.52% | 100% | -791.09% | - | -217.86% | -97.23% | 85.37% | 91.46% |
| Net Margin | -193.73% | -353.86% | -423.53% | -155.57% | -2719.8% | - | -9051.34% | -271.04% | -222.84% | -429.43% |
| Debt / Equity | 1.61x | 1.05x | 2.72x | 10.32x | 2.31x | 0.65x | 0.89x | - | - | 0.21x |
| Interest Coverage | -7.51x | -10.07x | -3.62x | -0.77x | -7.95x | -13.38x | -27.52x | -33.72x | -2.48x | -4.24x |
| FCF Conversion | 0.89x | 0.80x | 0.95x | 0.54x | 1.02x | 0.77x | 0.64x | 0.97x | 0.81x | 0.93x |
| Revenue Growth | -2.39% | -43.66% | -53.47% | 134.6% | -95.67% | -100% | - | 2093.3% | 18.54% | -10.49% |
PSTV Frequently Asked Questions
Plus Therapeutics, Inc. (PSTV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Plus Therapeutics, Inc. (PSTV) reported $5.2M in revenue for fiscal year 2025.
Plus Therapeutics, Inc. (PSTV) saw revenue decline by 10.5% over the past year.
Plus Therapeutics, Inc. (PSTV) reported a net loss of $22.4M for fiscal year 2025.
Dividend & Returns
Plus Therapeutics, Inc. (PSTV) has a return on equity (ROE) of -560.2%. Negative ROE indicates the company is unprofitable.
Plus Therapeutics, Inc. (PSTV) had negative free cash flow of $20.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More PSTV
Plus Therapeutics, Inc. (PSTV) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates